Original Biomedicals Co (ROCO:6483) Current Deferred Revenue: NT$0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6483 Original Biomedicals Co Ltd ROCO:6483
38 GF Score
Price NT$13.60
! 3 Warning Signs
View Full Analysis

What is Original Biomedicals Co Current Deferred Revenue?

Original Biomedicals Co ROCO:6483 -1.09% 38 Current Deferred Revenue is NT$0.00 Mil as of Jun. 2026. GuruFocus rates ROCO:6483 with a GF Score™ of 38/100. The stock has 3 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Original Biomedicals Co's current deferred revenue for the quarter that ended in Jun. 2026 was NT$0.00 Mil.

Original Biomedicals Co Current Deferred Revenue Related Terms

Original Biomedicals Co Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Original Biomedicals Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Original Biomedicals Co Current Deferred Revenue Chart

Original Biomedicals Co Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Original Biomedicals Co Semi-Annual Data
Dec11 Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6483
38GF Score
Original Biomedicals Co Ltd ROCO:6483
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$0.00 Mil mean?
Original Biomedicals Co (ROCO:6483) has a Current Deferred Revenue of NT$0.00 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Original Biomedicals Co and its competitors.
Is Original Biomedicals Co's Current Deferred Revenue too high?
Original Biomedicals Co's current Current Deferred Revenue is NT$0.00 Mil. Overall, Original Biomedicals Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Original Biomedicals Co's Current Deferred Revenue compare to ZTS?
Original Biomedicals Co's Current Deferred Revenue of NT$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Original Biomedicals Co and its competitors. Original Biomedicals Co's current Current Deferred Revenue is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Original Biomedicals Co stock overvalued right now?
Original Biomedicals Co (ROCO:6483) has a current Current Deferred Revenue of NT$0.00 Mil. The current Current Deferred Revenue is NT$0.00 Mil. Original Biomedicals Co's overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Original Biomedicals Co (ROCO:6483), the current Current Deferred Revenue is NT$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Original Biomedicals Co Business Description

Address No. 9, Nanke 2nd Road, 2 Floor-1, Xinshi District, Tainan, TWN, 74147
Original Biomedicals Co Ltd is a biopharmaceutical company engaged in the research and development of drugs. The company focuses on developing new drug formulations, drug delivery systems, and repurposing existing pharmaceutical products.
38GF Score

Get the complete analysis for ROCO:6483

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$13.60
Price